Section of Molecular Oncology & Developmental Therapeutics

Medicine & Life Sciences

1. Neoplasms 100%
2. HIV-1 76%
3. Renal Cell Carcinoma 68%
4. Breast Neoplasms 66%
5. Deltaretrovirus 64%
6. Mutation 52%
7. Human T-lymphotropic virus 1 48%
8. Pancreatic Neoplasms 47%
9. Adult T Cell Leukemia Lymphoma 44%
10. T-Lymphocytes 41%
11. Therapeutics 38%
12. Proteins 38%
13. Adenocarcinoma 35%
14. Heterografts 33%
15. HIV 31%
16. Drug Therapy 30%
17. Viruses 29%
18. Survival 29%
19. Clone Cells 28%
20. Genes 24%
21. Phosphotransferases 23%
22. Cell Line 22%
23. Growth 22%
24. Neoplasm Metastasis 22%
25. Triple Negative Breast Neoplasms 22%
26. Proteomics 21%
27. Prostatic Neoplasms 21%
28. Bone and Bones 21%
29. Trastuzumab 20%
30. gemcitabine 19%
31. Kidney Neoplasms 19%
32. Phosphorylation 19%
33. Osteoclasts 19%
34. Virion 18%
35. HIV-2 18%
36. Lymphocytes 17%
37. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 16%
38. Carcinogenesis 16%
39. Integrins 16%
40. Leukemia 16%
41. Apoptosis 16%
42. Macrophages 16%
43. Biomarkers 15%
44. Clinical Trials 15%
45. Immunotherapy 14%
46. Retroviridae 14%
47. Lymphoma 14%
48. Microphthalmia-Associated Transcription Factor 14%
49. Progression-Free Survival 14%
50. Genome 14%
51. Tumor Microenvironment 14%
52. Acquired Immunodeficiency Syndrome 13%
53. Androgen Receptors 13%
54. Melanoma 13%
55. vpr Gene Products 13%
56. Oncogenes 13%
57. 130-nm albumin-bound paclitaxel 12%
58. Interferons 12%
59. Transgenic Mice 12%
60. Safety 12%
61. Oncogene Proteins 12%
62. Amino Acids 12%
63. Castration 12%
64. Infections 11%
65. In Vitro Techniques 11%
66. Gene Expression 11%
67. Fluorouracil 11%
68. Zoledronic Acid 11%
69. DNA 11%
70. Virus Diseases 10%
71. Open Reading Frames 10%
72. Estrogen Receptors 10%
73. Ligands 10%
74. Peptides 10%
75. Epigenomics 10%
76. Nivolumab 10%
77. Mass Spectrometry 10%
78. Irinotecan 10%
79. Leucovorin 9%
80. Virus Replication 9%
81. Non-Hodgkin's Lymphoma 9%
82. sis Genes 9%
83. Urinary Bladder Neoplasms 9%
84. Everolimus 9%
85. Terminal Repeat Sequences 9%
86. Viral Proteins 9%
87. Protein-Tyrosine Kinases 9%
88. Tropism 9%
89. Radiotherapy 9%
90. Serine 8%
91. pX Genes 8%
92. Phenotype 8%
93. Bone Marrow 8%
94. Profilins 8%
95. Phosphatidylinositol 3-Kinases 8%
96. polyglutamine 8%
97. Tumor Burden 8%
98. ErbB Receptors 8%
99. Confidence Intervals 8%
100. Proteogenomics 8%